Literature DB >> 11226129

The GR127935-sensitive 5-HT(1) receptors mediating canine internal carotid vasoconstriction: resemblance to the 5-HT(1B), but not to the 5-HT(1D) or 5-ht(1F), receptor subtype.

D Centurión1, A Sánchez-López, P De Vries, P R Saxena, C M Villalón.   

Abstract

This study has further investigated the pharmacological profile of the GR127935-sensitive 5-HT(1) receptors mediating vasoconstriction in the internal carotid bed of anaesthetized vagosympathectomized dogs. One-minute intracarotid infusions of the agonists 5-hydroxytryptamine (5-HT; 0.1 - 10 microg min(-1); endogenous ligand) and sumatriptan (0.3 - 10 microg min(-1); 5-HT(1B/1D)), but not PNU-142633 (1 - 1000 microg min(-1); 5-HT(1D)) or LY344864 (1 - 1000 microg min(-1); 5-ht(1F)), produced dose-dependent decreases in internal carotid blood flow without changing blood pressure or heart rate. The responses to 5-HT were apparently resistant to blockade by i.v. administration of the antagonists SB224289 (300 microg kg(-1); 5-HT(1B)), BRL15572 (300 microg kg(-1); 5-HT(1D)) or ritanserin (100 microg kg(-1); 5-HT(2)). In contrast, the responses to sumatriptan were antagonized by SB224289, but not by BRL15572. In the animals receiving SB224289, but not those receiving BRL15572, the subsequent administration of ritanserin abolished the 5-HT-induced vasoconstriction and unmasked a vasodilator component. Similarly, in ritanserin-treated animals, the subsequent administration of SB224289, but not BRL15572, completely blocked the 5-HT-induced vasoconstriction, revealing vasodilatation. In animals receiving initially BRL15572, the subsequent administration of SB224289 did not affect (except at 10 microg min(-1)) the vasoconstrictor responses to 5-HT. Notably, in animals pretreated with 1000 microg kg(-1) of mesulergine, a 5-HT(2/7) receptor antagonist, 5-HT produced a dose-dependent vasoconstriction, which was practically abolished by SB224289. After BRL15572, no further blockade was produced and the subsequent administration of ritanserin was similarly inactive. These results suggest that the GR127935-sensitive 5-HT(1) receptors mediating canine internal carotid vasoconstriction resemble the 5-HT(1B) but not the 5-HT(1D) or 5-ht(1F), receptor subtype.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11226129      PMCID: PMC1572652          DOI: 10.1038/sj.bjp.0703913

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  26 in total

1.  The canine external carotid vasoconstrictor 5-HT1 receptor: blockade by 5-HT1B (SB224289), but not by 5-HT1D (BRL15572) receptor antagonists.

Authors:  P De Vries; A Sánchez-López; D Centurión; J P Heiligers; P R Saxena; C M Villalón
Journal:  Eur J Pharmacol       Date:  1998-11-27       Impact factor: 4.432

2.  Isochroman-6-carboxamides as highly selective 5-HT1D agonists: potential new treatment for migraine without cardiovascular side effects.

Authors:  M D Ennis; N B Ghazal; R L Hoffman; M W Smith; S K Schlachter; C F Lawson; W B Im; J F Pregenzer; K A Svensson; R A Lewis; E D Hall; D M Sutter; L T Harris; R B McCall
Journal:  J Med Chem       Date:  1998-06-18       Impact factor: 7.446

3.  SB-216641 and BRL-15572--compounds to pharmacologically discriminate h5-HT1B and h5-HT1D receptors.

Authors:  G W Price; M J Burton; L J Collin; M Duckworth; L Gaster; M Göthert; B J Jones; C Roberts; J M Watson; D N Middlemiss
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1997-09       Impact factor: 3.000

4.  Mediation of 5-HT-induced external carotid vasodilatation in GR 127935-pretreated vagosympathectomized dogs by the putative 5-HT7 receptor.

Authors:  C M Villalón; D Centurión; M Luján-Estrada; J A Terrón; A Sánchez-López
Journal:  Br J Pharmacol       Date:  1997-04       Impact factor: 8.739

5.  Alniditan, a new 5-hydroxytryptamine1D agonist and migraine-abortive agent: ligand-binding properties of human 5-hydroxytryptamine1D alpha, human 5-hydroxytryptamine1D beta, and calf 5-hydroxytryptamine1D receptors investigated with [3H]5-hydroxytryptamine and [3H]alniditan.

Authors:  J E Leysen; W Gommeren; L Heylen; W H Luyten; I Van de Weyer; P Vanhoenacker; G Haegeman; A Schotte; P Van Gompel; R Wouters; A S Lesage
Journal:  Mol Pharmacol       Date:  1996-12       Impact factor: 4.436

6.  Canine external carotid vasoconstriction to methysergide, ergotamine and dihydroergotamine: role of 5-HT1B/1D receptors and alpha2-adrenoceptors.

Authors:  C M Villalón; P De Vries; G Rabelo; D Centurión; A Sánchez-López; P Saxena
Journal:  Br J Pharmacol       Date:  1999-02       Impact factor: 8.739

7.  Characterisation of the 5-HT receptor binding profile of eletriptan and kinetics of [3H]eletriptan binding at human 5-HT1B and 5-HT1D receptors.

Authors:  C Napier; M Stewart; H Melrose; B Hopkins; A McHarg; R Wallis
Journal:  Eur J Pharmacol       Date:  1999-03-05       Impact factor: 4.432

8.  Characterisation of 5-HT receptors in human coronary arteries by molecular and pharmacological techniques.

Authors:  T Nilsson; J Longmore; D Shaw; E Pantev; J A Bard; T Branchek; L Edvinsson
Journal:  Eur J Pharmacol       Date:  1999-05-07       Impact factor: 4.432

9.  Characterization of LY344864 as a pharmacological tool to study 5-HT1F receptors: binding affinities, brain penetration and activity in the neurogenic dural inflammation model of migraine.

Authors:  L A Phebus; K W Johnson; J M Zgombick; P J Gilbert; K Van Belle; V Mancuso; D L Nelson; D O Calligaro; A D Kiefer; T A Branchek; M E Flaugh
Journal:  Life Sci       Date:  1997       Impact factor: 5.037

10.  5-HT1B receptor-mediated contractions in human temporal artery: evidence from selective antagonists and 5-HT receptor mRNA expression.

Authors:  R Verheggen; A G Hundeshagen; A M Brown; M Schindler; A J Kaumann
Journal:  Br J Pharmacol       Date:  1998-08       Impact factor: 8.739

View more
  2 in total

1.  Evidence for 5-HT(1B/1D) and 5-HT(2A) receptors mediating constriction of the canine internal carotid circulation.

Authors:  D Centurión; M I Ortiz; A Sánchez-López; P De Vries; P R Saxena; C M Villalón
Journal:  Br J Pharmacol       Date:  2001-03       Impact factor: 8.739

Review 2.  Cardiovascular responses produced by 5-hydroxytriptamine:a pharmacological update on the receptors/mechanisms involved and therapeutic implications.

Authors:  Carlos M Villalón; David Centurión
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-08-17       Impact factor: 3.000

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.